HEIDELBERG, Germany & THE WOODLANDS, Texas -- (BUSINESS WIRE) -- MolecularHealth announced today that its chief scientific officer, David Jackson, Ph.D., will present at this year’s American Association for Cancer Research (AACR) Precision Medicine Series Conference. The company’s poster presentation will highlight the value of computational selection and evaluation of biomarker evidence for cancer treatment decision support.
With the growing volumes of peer-reviewed literature reporting the relationships between genomic aberrations, tumor responsiveness to treatments, and associated patient outcomes, there has been a significant increase in the challenges facing clinicians to comprehensively identify and prioritize personalized treatments. To overcome such challenges, MolecularHealth developed a proprietary, automated computational system to assess the predicted effects of published genomic aberrations on drug responsiveness in a patient/disease-specific manner.
Dr. Jackson’s presentation, titled, “Automated Retrieval and Assessment of Biomarker-related Evidence for Cancer Treatment Decision Support,” will reveal supporting results of a study demonstrating the accuracy and efficiency of MolecularHealth’s analytics engine in assessing patient-relevant evidence, compared to a human expert with access to the same body of data.
MolecularHealth’s cancer treatment decision support offering, TreatmentMAP™, is based on this analytics engine and combines precision medicine with advanced data analysis to guide physicians to the safest and most effective cancer treatment options for their patients. The platform was commercially launched in the United States and Europe in April.
The abstract, poster board number A41, is scheduled to be presented as follows:
Date: Friday, June 20th
Time: From 7:00 a.m. to 9:30 a.m. ET
Session: Poster Session A
Location: Grand Cypress Ballroom GHI
Presenters: David Jackson, Ph.D., Alexander Zien, Ph.D.
The abstract will also be published in Proceedings, an AACR publication. This year’s conference will focus on Drug Sensitivity and Resistance: Improving Cancer Therapy and will be held on June 18th through the 21st at the Hyatt Regency Grand Cypress in Orlando, Florida.
MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.
In the U.S., TreatmentMAPTM is a laboratory developed test (LDT) performed at MolecularHealth’s CLIA-certified laboratory. In Europe, TreatmentMAP is the first registered medical device of its kind for personalized cancer medicine and offered through a network of certified physicians. MolecularHealth GmbH is certified according to DIN EN ISO 13485.
MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world’s leading healthcare, information technology and NGS companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, SAP AG and GATC Biotech.
Located in the centers of cancer research in Europe and U.S., the company is headquartered in Heidelberg, Germany, and its U.S. headquarters, including a CLIA-certified NGS lab, is located in The Woodlands, Texas. The company also has offices in Boston, Mass.